BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/5/2018 1:33:43 AM | Browse: 764 | Download: 873
 |
Received |
|
2018-03-30 08:42 |
|
Peer-Review Started |
|
2018-03-30 11:22 |
|
To Make the First Decision |
|
2018-05-17 03:15 |
|
Return for Revision |
|
2018-05-21 03:59 |
|
Revised |
|
2018-05-23 23:04 |
|
Second Decision |
|
2018-06-15 08:51 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-06-16 06:04 |
|
Articles in Press |
|
2018-06-16 06:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-07-03 03:48 |
|
Publish the Manuscript Online |
|
2018-07-05 01:33 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Emily M Lin, Jun Gong, Samuel J Klempner and Joseph Chao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Institutes of Health |
5K12CA001727-23 |
|
| Corresponding Author |
Joseph Chao, MD, Assistant Professor, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, United States. jchao@coh.org |
| Key Words |
Immunotherapy; Programmed cell death 1; Programmed death ligand 1; Microsatellite instablility; Gastric cancer |
| Core Tip |
Programmed death ligand 1 (PD-L1) and microsatellite instability have recently entered into clinical practice as recommended biomarker testing for the use of immune checkpoint inhibitors in gastroesophageal cancer. However, PD-L1 still does not carry the highest sensitivity and specificity with variability in testing reported. Incorporation of PD-L1 expression from the tumor microenvironment with counting of immune cells appears to be the most effective strategy to date. Future efforts focusing on composite biomarkers in ongoing research from combinatorial immuno-oncology strategies are necessary to drive the field forward. |
| Publish Date |
2018-07-05 01:33 |
| Citation |
Lin EM, Gong J, Klempner SJ, Chao J. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World J Gastroenterol 2018; 24(25): 2686-2697 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i25/2686.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i25.2686 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
